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improve sleep apnea in patients with PH. In addition, oxygen 
therapy also improved exercise performance. Further stud-
ies are needed to corroborate the efficacy of these and other 
treatments.  © 2016 S. Karger AG, Basel 
 Introduction 
 Precapillary  pulmonary hypertension (PH) and right 
ventricular heart failure occur in certain patients with 
sustained hypoxemia due to obesity hypoventilation syn-
drome  [1] and severe sleep-related hypoventilation, and 
in high-altitude residents suffering from chronic moun-
tain sickness  [2] . Whether precapillary PH may also de-
velop as a consequence of intermittent hypoxemia during 
sleep such as in patients with obstructive sleep apnea 
(OSA) is controversial. While up to 50% of adults in 
Western countries are estimated to be affected by various 
severities of OSA  [3–5] , only a minor fraction of these in-
dividuals are considered to suffer from precapillary PH 
 [6] . Conversely, among patients with precapillary PH, ei-
ther pulmonary arterial or chronic thromboembolic 
(WHO classes I or IV), a high prevalence of central sleep 
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 Abstract 
 Among patients with sleep apnea the reported prevalence 
of precapillary pulmonary hypertension (PH) has varied 
largely, depending on patient selection, disease definition, 
and associated conditions, in particular chronic pulmonary 
disease. However, in the absence of comorbidities, PH seems 
to be rare in patients with sleep apnea. Conversely, sleep-
related breathing disorders have been commonly found in 
patients with PH and they have been associated with an im-
paired quality of life. Since sleep-related breathing disorders 
may affect the pulmonary circulation and vice versa, patients 
with sleep-related breathing disorders should be evaluated 
for risk factors, symptoms and clinical signs of PH and right 
ventricular heart failure and patients with PH should be eval-
uated for sleep apnea. Therapeutic options for patients with 
sleep apnea and PH may include supplemental oxygen, 
drugs and positive pressure ventilation. Both nocturnal oxy-
gen administration and acetazolamide have been shown to 
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apnea (CSA) and OSA has been observed suggesting a 
pathophysiologic link  [7] .
 In patients with postcapillary PH due to severe left 
ventricular heart failure (WHO class II), Cheyne-Stokes 
respiration/CSA (CSR/CSA) is quite common and this 
association is considered to indicate a poor prognosis. 
Compared to sleep-disordered breathing (SDB) in the 
context of left ventricular failure, which has been the top-
ic of a review article in this journal  [8] , SDB in association 
with precapillary PH has gained much less attention. 
Therefore, the aim of the current review is to analyze the 
literature on this association with a particular focus on 
the pathophysiologic mechanisms linking SDB and pre-
capillary PH. We further review the prevalence and im-
portance of precapillary PH in patients with SDB and of 
SDB in patients with PH, and we analyze the prognostic 
and therapeutic implications of SDB in association with 
PH.
 Mechanisms Linking Precapillary PH and SDB 
 During normal sleep, there is a fall in heart rate and 
systemic arterial blood pressure with lowest values in 
deep non-rapid eye movement (NREM) sleep  [9] . In rap-
id eye movement (REM) sleep, pulmonary arterial pres-
sure (PAP) becomes unstable and increases compared to 
NREM sleep  [10] . However, no relevant differences in 
PAP were seen between the first and the second half of a 
night in healthy individuals, which may indicate a lack of 
dependence of PAP on NREM and REM sleep stage  [11] .
 Excessive rises in PAP and SDB may be mutually linked 
by either direct effects or via comorbid conditions ( Fig. 1 ). 
Thus, hypoxemia during sleep due to hypoventilation or 
apneas/hypopneas may induce PH through hypoxic and/
or hypercapnic pulmonary vasoconstriction and sympa-
thetic activation as detailed below. Conversely, it has been 
suggested that precapillary PH associated with right ven-
tricular failure may promote instability of ventilatory con-
trol leading to sleep apnea through similar mechanisms as 
in left ventricular failure with CSR/CSA  [12] . Further-
more, patients suffering from SDB in association with 
other conditions predisposing to an elevated PAP such as 
chronic lung disease, in particular chronic obstructive 
pulmonary disease (COPD), chronic alveolar hypoventi-
lation related to chest wall deformities or neuromuscular 
disease with respiratory muscle weakness, may be suscep-
tible to developing precapillary PH. According to epide-
miologic studies in overweight patients, both hypoxia and 
hypercapnia are associated with precapillary PH, although 
their relative significance has not been conclusively as-
sessed  [13] . Thus, in one study in obese patients with PH 
 [14] , PaCO 2 was correlated with PAP; 3 months of treat-
ment with noninvasive ventilation reduced both PaCO 2 
and PAP. Since PaO 2 was also improved, the independent 
effect of hypercapnia could not be assessed. Nevertheless, 
other studies in preparations of pulmonary arteries  [15] , 
animal models  [16, 17] and healthy volunteers  [18, 19] 
have suggested an independent effect of hypercapnia in-
ducing PH by pulmonary vasoconstriction through an 
NO-mediated pathway and by enhanced vasoreactivity of 
pulmonary arteries. Thus, intermittent sleep-related hy-
poxemia and hypercapnia alone or in combination with 
chronic hypoxemia and structural alterations of the lung 
may predispose to precapillary PH, right ventricular dys-
function and failure. The paucity of conclusive data on 
this topic may be due to the complexity of measuring pres-
sure and flow in the pulmonary circulation by right heart 
catheter. Novel echocardiographic and magnetic reso-
nance imaging and other techniques may provide further 
insights into these interactions in the future  [20, 21] . Var-
ious pathophysiologic mechanisms linking PH and SDB 
will be discussed in the following.
 OSA and Precapillary PH 
 Patients with OSA may show acute or chronic hemo-
dynamic changes associated with intermittent hypox-
emia. Various pathophysiologic mechanisms have been 
discussed. Comorbid conditions additionally play an im-
portant role.
Comorbid
conditions
Pulmonary
hypertension
1
2 2
Sleep-
disordered
breathing 3
 Fig. 1. The interaction between sleep-disordered breathing and 
precapillary pulmonary hypertension may be mutually mediated 
by direct effects (arrows labelled 1 and 3) or via comorbid condi-
tions (arrow 2), in particular, chronic respiratory diseases such as 
chronic obstructive pulmonary disease or obesity hypoventilation 
syndrome. 
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 Hypoxic and Hypercapnic Pulmonary Vasoconstric-
tion.  Hypoxic pulmonary vasoconstriction is an impor-
tant mechanism that contributes to maintaining an ade-
quate ventilation-perfusion relationship (V/Q) in the 
lungs  [22] . Thus, reducing ventilation in a part of the 
lungs leads to regional hypoxia with vasoconstriction that 
reduces shunt perfusion. Motley and Cournand  [23] 
showed that breathing a hypoxic gas mixture containing 
10% oxygen induced a rise in PAP. Persistent pulmonary 
vasoconstriction due to hypoxia may result in vascular 
remodeling and thus chronic precapillary PH. As out-
lined above, hypercapnia may also promote pulmonary 
vasoconstriction in conjunction with or independent of 
hypoxia. Both hypoxia and hypercapnia are therefore 
considered to be responsible for the development of pre-
capillary PH in chronic hypoventilation due to obesity or 
lung diseases  [24] . Some animal studies have suggested 
that nocturnal intermittent hypoxia in OSA is sufficient 
to cause persistent daytime PH und right ventricular dys-
function  [25] but this is debated in the case of human 
OSA. Some studies on this topic included patients with 
coexisting conditions such as COPD or obesity resulting 
in sustained hypoxemia by ventilation-perfusion mis-
match, diffusion impairment or hypoventilation  [26–30] , 
others were performed in sleep apnea patients without 
comorbidities  [31–33] . It is conceivable that patients with 
chronic lung disease such as COPD that may cause hy-
poxemia and a reduced pulmonary vascular bed, or pa-
tients with hypoxemia due to obesity associated with hy-
poventilation may be at particular risk to develop pulmo-
100
50
SpO2,
%
EMGGG
150
75
HR,
bpm
100
0
PAP,
mm Hg
200
0
Psa,
mm Hg
Rib
EOG
EEG
Abdo.
Flow
NREM (stage I–II) REM NREM (stage I–II)
Tonic Phasic
1 min
 Fig. 2. Example of polysomnographic recording during phasic and 
tonic rapid eye movement (REM) sleep. There are major rises in 
both systemic and pulmonary artery pressure (arrows) during ap-
neas in phasic REM sleep (adapted from Niijima et al.  [10] ). Abdo., 
abdomen; HR, heart rate; PAP, pulmonary artery pressure; Psa, 
systemic arterial pressure. 
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nary vascular remodeling and persistent elevations in 
PAP in the presence of aggravated hypoxemia during 
sleep by OSA.
 Sympathetic Overstimulation. In patients with OSA, 
breathing efforts against an occluded airway cause large 
fluctuations in systemic blood pressure associated with 
hypoxemia, arousals and surges of sympathetic tone  [34] . 
Moreover, major rises in both systemic and PAP during 
long apneas in phasic REM sleep have been described 
( Fig. 2 )  [10] . The large arterial pressure swings associated 
with sympathetic overstimulation in OSA patients induce 
vascular shear stress and promote endothelial dysfunc-
tion  [35–37] . Repetitive hypoxia and reoxygenation may 
upregulate hypoxia-inducible factors, vascular endothe-
lial growth factor and erythropoietin, and trigger inflam-
matory processes  [38] . These mechanisms may lead to 
elevations in PAP that persist even during daytime and 
over prolonged time as suggested for the pathophysiology 
of systemic hypertension in OSA.
 Increased Inspiratory Effort. In OSA, the increased in-
spiratory effort against an occluded airway causes large 
intrathoracic pressure swings that create mechanical 
stress on the aorta and the left ventricle and increase af-
terload contributing to the development of systemic hy-
pertension and cardiovascular disease in affected pa-
tients. Acute right ventricular enlargement because of in-
creased venous return may impair left ventricular filling. 
Together, these mechanisms may lead to an increased 
pulmonary venous pressure, and postcapillary PH  [39] . 
Conceivably, similar mechanisms might also lead to ele-
vated PAP. Negative intrathoracic pressure during OSA 
might additionally cause PAP to rise by increased pulmo-
nary vascular resistance  [40] . A similar mechanism has 
recently been documented in patients with COPD expe-
riencing major increases in pleural pressure swings dur-
ing exercise that were accompanied by rises in PAP  [41] .
 Precapillary PH and Ventilatory Instability 
 Several studies have shown that severe precapillary PH 
associated with right ventricular failure and low cardiac 
output may be associated with SDB including CSR/CSA 
as well as OSA, similar to what is observed in patients with 
severe left ventricular failure and postcapillary PH  [7, 42, 
43] . The mechanisms responsible for the destabilizing ef-
fect of PH on control of breathing remain elusive. How-
ever, factors that predispose to CSR/CSA in left ventricu-
lar failure may also be relevant in right ventricular failure. 
For example, increased chemosensitivity associated with 
sympathetic stimulation may promote an overshooting 
ventilatory response to apneas/hypopneas. Moreover, an 
excessive circulatory delay due to a reduced cardiac out-
put in severe precapillary PH may prolong the time re-
quired to transport oxygenated blood from the lungs to 
the chemoreceptors so that the feedback to the respira-
tory center is desynchronized  [8, 44, 45] . Patients with 
precapillary PH, especially those with right ventricular 
heart failure and fluid overload, may possibly exhibit noc-
turnal breathing instability through rostral fluid redistri-
bution at night as suggested by studies in patients with 
systemic hypertension  [46] .
 Prevalence and Importance of PH in SDB 
 There is increasing evidence of an association of SBD 
with systemic hypertension, incidence of stroke, heart 
failure, myocardial infarction, arrhythmias and sudden 
cardiac death  [47–49] . Similar data on potentially adverse 
effects of SDB in patients with PH are not available. A re-
search of the literature on the prevalence of precapillary 
PH in patients with SDB unselected for the absence of 
comorbidities as well as in patients with concomitant 
lung and heart diseases has identified the studies summa-
rized in  Table 1 .
 In observational case studies of OSA patients unselect-
ed for absence of comorbidities ( Table 1 , upper part), the 
prevalence of PH has varied largely between 17 and 60% 
 [27, 50] . When studies excluded patients with coexisting 
lung and heart diseases, the prevalence of OSA-related 
PH was estimated at up to 40% ( Table 1 , lower part)  [31, 
32, 50–52] ; however, in only 2 of these studies  [31, 51] was 
the current definition of PH (mean PAP >25 mm Hg) ap-
plied. The wide range of prevalence rates may be due to 
differences in patient selection, disease definition and 
methodological differences, i.e., invasive pressure mea-
surement with right heart catheter versus Doppler echo-
cardiography. The value and limitations of Doppler echo-
cardiography in the evaluation of PH patients have been 
addressed in the recent ESC/ERS guidelines  [53] . Addi-
tionally, using PAP cutoff values for defining the presence 
of PH that are different than the current one (mean PAP 
 ≥ 25 mm Hg) might have confounded the prevalence 
rates. Data from appropriately powered epidemiologic 
studies using right heart catheter data and the current 
definition of PH are not available to date.
 In a large sample of 220 patients with OSA  [27] , 17% 
revealed a mean PAP of >20 mm Hg (i.e., this study used 
a cutoff for defining PH that was lower than the mean 
PAP  ≥ 25 mm Hg required for the diagnosis of PH ac-
cording to current standards). Some of these patients 
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First author 
[Ref.], year
Topic Design Participants Outcome Remarks
Patients with obstructive sleep apnea (mixed group of patients with and without coexistent lung disease)
Fletcher 
[50], 1987
precapillary 
PH in OSA 
with lung 
disease
case 
series
among 24 patients 
with OSA, 19 had 
coexisting lung 
disease, 5 had no 
coexisting lung 
disease
in 15 of 24 patients, right heart 
catheter data were available; mPAP 
was >25 mm Hg in 9 of these 15 
patients (in 7 with and 2 without 
coexistent lung disease)
Weitzenblum 
[30], 1988
precapillary 
PH in OSA 
with and 
without lung 
disease
case 
series
46 with OSA; 
no overt COPD
9 of 46 patients had mPAP >20; these 
had lower PaO2, FEV1, FVC, higher 
PaCO2, but similar AHI than those 
with lower mPAP; predictors of PH: 
pO2, pCO2 FEV1, FEV1/FVC
precapillary PH was not 
correlated with AHI
Krieger 
[29], 1989
precapillary 
PH in OSA 
with lung 
disease
case 
series
100 with OSA; 
AHI >5/h
19/100 OSA patients had mPAP >20 
mm Hg; they had lower pO2, higher 
pCO2, and higher AHI than those with 
lower mPAP; predictors of PH: FEV1, 
pO2, pCO2
Laks 
[13], 1995
precapillary 
PH in OSA 
with and 
without lung 
disease
case 
series
100 with OSA 
(AHI >20/h; 
oxygen 
desaturations >4%)
42/100 OSA patients had mPAP >20 
mm Hg; of these 6 with normal pO2, 
pCO2 36 – 65 mm Hg;
predictors of PH: pO2, (pCO2) FEV1
FEV1 %pred. not given; 
incomplete multivariate 
regression (BMI not 
evaluated). 6 patients with 
OSA and precapillary PH 
but normal PaO2
Chaouat 
[26], 1995
COPD in 
OSA
case 
series
265 with OSA 
AHI >20/h of these
30 with coexistent 
COPD FEV1/FVC 
≤60%
OSA/COPD overlap in 30/265 (11%); 
these patients had reduced lung 
function (obstructive pattern, FEV1/
FVC ≤60%), were male, had similar 
BMI, lower SaO2, impaired arterial 
blood gases, and a higher mean mPAP 
of 20 mm Hg compared to OSA 
patients without COPD (mean mPAP 
15 mm Hg); predictors of mPAP: 
PaCO2, FEV1, airway resistance, SaO2
Chaouat 
[27], 1996
precapillary 
PH in OSA 
with and 
without lung 
disease
case 
series
220 with OSA 
AHI >20
37/220 had mPAP >20 mm Hg; 
16/220 had mPAP >25 mm Hg;
OSA patients with mPAP >20 had 
lower PaO2, nocturnal SaO2,FEV1, 
FEV1/FVC, higher AHI, PaCO2
predictors of PH: PaCO2, FEV1, 
mean nocturnal SpO2
precapillary PH in OSA 
is linked to COPD, 
hypoxemia, hypercapnia
Sanner 
[33, 63], 1997
precapillary 
and 
postcapillary 
PH in OSA 
without lung 
disease
Case 
series
92 with OSA and 
no evidence of 
lung disease AHI 
>10/h
18/92 had mPAP >20 mm Hg, 8 of 
these had also PCWP >13 mm Hg
there is a possible overlap 
of patients [33, 62]
 Table 1.  Pulmonary artery pressure in patients with sleep-disordered breathing
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seem to have suffered from COPD. Laks et al.  [13] studied 
a heterogeneous group of 100 patients with OSA. The 
mean daytime PAP was 21 mm Hg and the apnea/hypo-
pnea index (AHI) varied between 20 and 100 events/h. 
Forty-two patients had a mean PAP >20 mm Hg (a defi-
nition of PH different from current standards). Several 
patients were hypoxemic and hypercapnic during day-
time and some had impaired pulmonary function sug-
gesting coexisting COPD. In addition, some patients were 
very obese; PaO 2 , PaCO 2 and FEV 1 explained 33% of the 
variation in PAP suggesting that the high prevalence of 
precapillary PH of 42% in this cohort may have been re-
Table 1 (continued)
First author 
[Ref.], year
Topic Design Participants Outcome Remarks
Patients with obstructive sleep apnea without coexistent lung or heart disease
Fletcher [50], 
1987
precapillary 
PH in OSA 
without lung 
disease
case 
series
among 24 patients 
with OSA, 5 had 
no coexisting lung 
disease
2 of 5 patients had a slightly elevated 
mPAP of 26 and 27.7 mm Hg
Sajkov 
[51], 1994 
precapillary 
PH in OSA 
without lung 
disease
case 
series
27 patients with 
OSA, AHI >10/h, 
no lung or heart 
disease
11/27 patients had mPAP >20 (range 
20 – 26) mm Hg; predictor of mPAP 
was PaO2 only, not pulmonary 
function or BMI or AHI
some OSA patients 
responded excessively to 
hypoxia suggesting 
remodeling of pulmonary 
vasculature; the cutoff for 
PH in this study was 
20 mm Hg (not ≥25)
Sajkov 
[52], 1999
precapillary 
PH in OSA 
without lung 
disease
case 
series
32 with OSA with 
AHI >10/h and 
PFT >80% pred., 
no cardiac disease
11/32 OSA patients had mPAP >20 
mm Hg (range 20 – 31); no difference 
in pulmonary function or BMI 
between groups; isocapnic hypoxia 
with SpO2 80% induced a greater rise 
in mPAP in those with mPAP >20 
mm Hg at baseline; hyperoxia reduced 
mPAP more in patients with mPAP 
<20 mm Hg at baseline; dobutamin 
infusion increased mPAP more in 
patients with mPAP >20 mm Hg at 
baseline than in remaining patients; 
mPAP was correlated with airway 
closure during tidal breathing
some OSA with normal 
lung function and no 
cardiac disease may have 
mild precapillary PH; the 
cutoff for PH in this study 
was 20 mm Hg 
(not ≥25 mm Hg)
Bady 
[32], 2000
precapillary 
PH in OSA 
without lung 
disease
case 
series
44 with OSA 
(AHI >5/h), 
normal pulmonary 
function (FEV1 
>70%, FEV1/FVC 
>60%)
mPAP >20 mm Hg, PCWP <15 mm 
Hg in 12/44 OSA patients without 
lung disease; AHI in OSA with and 
without mPAP >20 mm Hg was not 
different; predictors of mPAP: PaO2, 
PaCO2, nocturnal SpO2, higher BMI
no patients with lung 
disease. mPAP related to 
BMI and pO2, not AHI; 
the cutoff for PH in this 
study was 20 mm Hg 
(not ≥25 mm Hg)
Alchanatis 
[31], 2001
precapillary 
PH in OSAS, 
effect of 
CPAP
case 
control 
study, 
before 
after 
CPAP
29 OSA patients 
with AHI >15/h: in 
19 of these right 
heart catheter data 
were shown
3/19 of OSA patients had mPAP ≥25 
mm Hg; mPAP was correlated with 
age, PaO2, BMI
 Several studies used definitions of precapillary pulmonary hypertension (PH) that are not consistent with the current definition of 
mPAP ≥25 mm Hg and PCWP <15 mm Hg, the criteria for PH are indicated for individual studies. OSA, obstructive sleep apnea; COPD, 
chronic obstructive pulmonary disease; mPAP, mean pulmonary artery pressure; AHI, apnea/hypopnea index; BMI, body mass index; 
CTEPH, chronic thromboembolic pulmonary hypertension; CSR, Cheyne-Stokes respiration; PFT, pulmonary function testing; SDB, 
sleep-disordered breathing; CPAP, nocturnal continuous positive airway pressure treatment; PCWP, pulmonary capillary wedge 
pressure.
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lated to coexistent disorders and to the liberal PH defini-
tion of mean PAP >20 mm Hg at that time.
 Sajkov et al.  [51] compared a group of OSA patients 
with mildly elevated PAP still within the normal range 
(mean PAP of 22.8 mm Hg) with another group of pa-
tients with a similar degree of OSA but low normal PAP 
(mean PAP of 14.6 mm Hg). In both groups, no heart or 
lung disease could be found even by detailed examina-
tions, but the patients with higher PAP had lower PaO 2 . 
The authors speculated that these patients had an exces-
sive hypoxic response of the pulmonary vasculature that 
promoted the development of PH in combination with 
OSA.
 To further corroborate the mechanisms involved in 
the rise of PAP in certain patients with OSA, Sajkov et al. 
 [52] studied 32 OSA patients without any evidence of car-
diac or pulmonary disease. Eleven of them had a mean 
PAP >20 mm Hg but a similar AHI, body mass index and 
daytime arterial blood gas values as the remainder of the 
patients with a mean PAP <20 mm Hg. Although both 
groups of OSA patients had normal spirometry, the pa-
tients with higher mean PAP had a reduced closing vol-
ume measured by the nitrogen washout technique. The 
difference between functional residual capacity and clos-
ing volume was negative indicating that some patients ex-
perienced intermittent closure of peripheral airways dur-
ing tidal breathing. This might have predisposed them to 
a V/Q mismatch and hypoxemia thereby contributing to 
elevated PAP. In the same group of OSA patients, Sajkov 
et al.  [52] evaluated the hypoxic pulmonary vasoreactiv-
ity by exposing patients to an inspiratory fraction of oxy-
gen (FiO 2 ) of 11, 21 and 50% while PAP was monitored. 
Patients with elevated PAP at baseline on room air above 
20 mm Hg had a brisker response to changes in FiO 2 than 
patients with lower baseline mean PAP. In addition, chal-
lenges with dobutamin infusion were performed. With 
increases in cardiac output, PAP rose significantly more 
in patients with mean PAP >20 mm Hg at baseline com-
pared to the rest of the patients. These findings were con-
sidered to be consistent with vascular remodeling in some 
of the OSA patients  [52] ( Fig. 3 ).
 SDB in Patients with Precapillary PH 
 So far, the direct or indirect effects of SDB on precapil-
lary PH had been discussed. There is evidence that the 
relation may also act in the opposite direction, so that 
precapillary PH may trigger SDB ( Fig. 1 ). As many fea-
tures of patients with left ventricular failure and SDB, 
40
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a b
 Fig. 3.  a Evaluation of hypoxic pulmonary vasoreactivity by expos-
ing patients with obstructive sleep apnea to an FiO 2 of 11, 21 and 
50%. Patients with a mean pulmonary artery pressure (PAP) of >20 
mm Hg at baseline on room air had a brisker response to changes 
in FiO 2 than patients with a mean pulmonary artery pressure  ≤ 20 
mm Hg suggesting an exaggerated hypoxic response of the pulmo-
nary vasculature of patients with initially higher pulmonary artery 
pressures.  b During a dobutamin challenge test that increased car-
diac output (CO) pulmonary artery pressure increased to higher 
values in patients with a mean pulmonary artery pressure of >20 
mm Hg at baseline compared to the rest of the patients in whom 
PAP reached a plateau at values of less than 20 mm Hg (adapted 
from Sajkov et al.  [52] ).  *   p < 0.05 vs. group II (PAP  ≤ 20),  †   p < 0.05 
vs. FiO 2 50%,  ‡   p < 0.05 vs. FiO 2 21%. 
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such as low cardiac output, increased sympathetic tone, 
and arrhythmia, are also common in patients with pre-
capillary PH and right ventricular failure, some authors 
have also looked at SDB in patients with precapillary PH 
of different origins. These studies are summarized in  Ta-
ble 2 .
 Schulz et al.  [54] were the first to describe CSR/CSA in 
patients with pulmonary arterial hypertension (PAH; 
WHO class I). Patients had typical periodic breathing 
with waxing and waning of ventilation. Fourteen had an 
AHI of <20/h and 6 had an AHI >20/h with nearly exclu-
sively central events consistent with CSR/CSA. In order 
to further evaluate the prevalence and type of sleep-relat-
ed breathing disturbances in PH patients, we performed 
a prospective study in consecutive patients with either 
PAH or chronic thromboembolic pulmonary hyperten-
sion  [7] . In none of these patients had SDB been suspect-
ed on clinical grounds and most of them had been treated 
for PAH/chronic thromboembolic pulmonary hyperten-
sion with various drugs for several months or years. A 
total of 38 patients were studied. In  Figure 4 , the total AHI 
in each patient and the relation between central and ob-
structive events are shown. Eighteen patients or 47% had 
an elevated AHI of >10/h. The large majority had pre-
 Table 2. Sleep-disordered breathing among patients with precapillary pulmonary hypertension
First author 
[Ref.], year
Topic Design Participants Outcome Remarks
Rafanan 
[56], 2001 
Nocturnal 
hypoxemia in 
precapillary PH
case 
series
13 with PAH 10/13 were nocturnal desaturators, i.e., 
>10% of nighttime with SpO2 <90%; 
desaturators had lower FEV1 and PaO2, 
higher hemoglobin concentration
Schulz 
[54], 2002 
CSR in precapillary 
PH
case 
series
20 with PAH CSR in 6/20 who had more severe pre-
capillary PH;  nasal oxygen eliminated 
CSR
suggests effect 
of oxygen
Schulz
[64], 2004 
CSR in precapillary 
PH
case 
report
1 female with PAH polysomnography before and after 
lung transplantation shows 
disappearance of CSR
Minai 
[55], 2007 
nocturnal 
hypoxemia in 
precapillary PH
case 
series
43 with PAH 30/43 were desaturators with >10% of 
the night-time with SpO2 <90%; 
desaturators had higher hemoglobin, 
higher brain natriuretic peptide, higher 
mPAP, lower cardiac index
Ulrich 
[7], 2008 
SDB in precapillary 
PH
case 
series
38 with precapillary
PH (PAH 23, CTEPH 
15)
17/38 had AHI >10/h; 4 had OSA; 
sleep-disordered breathing was 
associated with reduced quality of life
Prisco
[43], 2011 
SDB in precapillary 
PH
case 
series
28 with precapillary
PH (PAH 9, associated 
PH 21
precapillary PH severity best correlated 
with combination of AHI and time of 
the night spent with SpO2 <90%
Hildenbrand
[65], 2012 
nocturnal 
hypoxemia in PAH, 
CTEPH
case 
series
63 with precapillary
PH (44 PAH, 
19 CTEPH)
77% spent >10% of the nighttime with 
SpO2 <90%
Jilwan
[42], 2013 
SDB in PAH,
CTEPH
case 
series
46 with precapillary
PH (29 PAH, 
17 CTEPH)
89% had sleep apnea,
83% had nighttime hypoxemia
BMI <35
FEV1 >60%
Dumitrascu
[66], 2013 
SDB in various 
forms of pre-
capillary PH
case 
series
169 with precapillary 
PH (28 PAH, 
51 CTEPH, 16 colla-
gen vascular disease, 
59 chronic lung disease,
15 other)
26.6% had sleep apnea,
AHI >10/h, of these 16.0 % had OSA, 
10.6% had CSA
PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; CSR, Cheyne-Stokes respiration; CTEPH, chronic thrombo-
embolic pulmonary hypertension; mPAP, mean pulmonary artery pressure; SDB, sleep disordered breathing; OSA, obstructive sleep 
apnea; AHI, apnea/hypopnea index; BMI, body mass index
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dominant CSR but 4 patients also had more than 10 ob-
structive events per hour. No significant differences in 
hemodynamics, arterial blood gases or pulmonary func-
tion between the groups with and without increased AHI 
were found. Polysomnography and pulse oximetry were 
used to assess SDB in the study by Ulrich et al.  [7] to eval-
uate the diagnostic accuracy of the simple technique in 
this setting. Although pulse oximetry had been proposed 
as part of the routine evaluation of patients with PH to 
detect nighttime hypoxemia  [55] , oximetry alone re-
vealed a poor diagnostic performance (area under the re-
ceiver operating characteristic curve of only 0.66 ± 0.14) 
in identifying patients with an AHI  ≥ 10, when compared 
with polysomnography  [7] . Thus, pulse oximetry alone 
cannot be recommended as diagnostic tool for SDB in PH 
patients. Whereas in some studies on the association of 
precapillary PH with SDB nocturnal hypoxemia without 
sleep apnea was the predominant finding  [55, 56] , others 
found sleep apnea without severe persistent hypoxemia 
 [7, 54] or a combination of both persistent hypoxemia 
and sleep apnea  [42, 43] . In a most recent study in Kyrgyz 
highlanders, a high prevalence of mainly OSAs was found 
among individuals with high-altitude PH, a particular 
form of precapillary PH occurring in life-long residents 
at altitudes >2,500 m. This observation suggests that in-
dividuals exposed to the combined stimuli of chronic hy-
poxemia due to high-altitude residence and intermittent 
nocturnal hypoxemia due to sleep apnea may be more 
susceptible to PH compared to highlanders without sleep 
apnea  [57] .
 Treatment of PH in SBD 
 Tracheostomy and supplemental oxygen have been 
shown to reduce PAP in patients with COPD and night-
time hypoxemia  [58] but this intervention (tracheosto-
my) is rarely performed nowadays. Limited data on ef-
fects of continuous positive airway pressure (CPAP) 
treatment in patients with OSA on PAP are available. In 
a case-control study by Alchanatis et al.  [31] , 29 patients 
without evidence of pulmonary or cardiac disease were 
studied with Doppler echocardiography before and af-
ter 6 months of CPAP treatment. Of these 29 patients, 
6 had mild precapillary PH. The control group consist-
ed of 12 healthy subjects. Older subjects and those with 
increased body mass index in the OSA group were more 
prone to suffer from (generally mild) precapillary PH 
and 6 months of CPAP caused a significant fall in PAP 
in hyper- and normotensive patients pointing to OSA 
as an independent risk factor for the development of 
precapillary PH. In another study including patients 
with moderate to severe OSA, 4 months of CPAP sig-
nificantly reduced the PAP, especially when the PAP 
was elevated at baseline  [59] . Moreover, the pulmonary 
vascular response to hypoxia decreased after CPAP 
treatment  [59] . In a randomized crossover trial in pa-
tients with OSA using sham or effective CPAP for 12 
Nocturnal oxygen
Azetazolamide
–50 0 50
Change in 6MWD, m
0
10
20
30
40
50
60
70
1
Patient number
Ap
ne
a/
hy
po
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ea
 in
de
x,
 1
/h
6 11 16 21
Central
Obstructive
26 31 36
 Fig. 4. Apnea/hypopnea index in 38 patients with precapillary pul-
monary hypertension. The bars are ordered in descending order 
of the total apnea/hypopnea index with the black part representing 
the obstructive and the gray part the central events. A value of  ≥ 10 
was observed in 45% of patients, the median value was 8/h (repro-
duced from Ulrich et al.  [7] ). 
 Fig. 5. Results of a randomized, placebo-controlled double-blind 
trial evaluating the effect of 1 week of nocturnal oxygen therapy 
and acetazolamide, respectively, on the 6-min walk distance 
(6MWD) in patients with precapillary pulmonary hypertension 
and sleep-related breathing disturbances. Mean differences and 
95% confidence intervals of the 6-min walk distance between ac-
etazolamide and placebo and between oxygen and sham oxygen 
(ambient air) are shown (reproduced from Ulrich et al.  [62] ). 
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weeks, PAP was reduced significantly by CPAP  [60] . 
The studies mentioned above have not included right 
heart catheter data to demonstrate whether improve-
ment in pulmonary hemodynamics occurred because of 
improvement in precapillary PH or by improving left 
ventricular function.
 Supplemental nocturnal oxygen has been used in pa-
tients with nocturnal hypoxemia-related PH. In COPD 
patients, long-term home oxygen therapy did not im-
prove survival in patients with mild to moderate hypox-
emia or in those with arterial desaturation at night only 
 [61] . It is uncertain whether this also applies to PH pa-
 Table 3. Interventional studies in patients with precapillary pulmonary hypertension and sleep apnea
First author 
[Ref.], year
Topic Design Participants Outcome Remarks
Alchanatis 
[31], 2001  
precapillary PH
in OSAS, effect 
of CPAP
case control 
study, before 
after CPAP
33 with OSA AHI 
>15/h: 29 with 
OSA
at baseline and 
after CPAP, 12 
snorers
OSA patients had higher mPAP 
than controls; 3/19 OSA had 
mPAP >25 mm Hg; mPAP was 
correlated with age, PaO2, BMI. 
CPAP reduced mPAP in all OSA 
patients (see also Table 1)
baseline assessment 
by right heart 
catheterization, 
follow-up assessment 
of PAP by 
echocardiography
Sajkov
[59], 2002 
precapillary PH
in OSAS, effect
of CPAP
observational 
study on CPAP 
effect on 
precapillary 
PH in OSA 
without lung 
disease
20 with OSA of 32 
OSA with AHI >10 
and pulmonary 
function variables 
>80 % predicted, 
no cardiac disease
5/20 OSA had mPAP >20 mm 
Hg; sPAP was reduced in all 
patients after 4 months of CPAP 
except in 1 non-compliant 
patient; hypoxic vasoreactivity
was reduced and flow response 
was shifted downward in a 
parallel fashion; systemic blood 
pressure was also reduced
results may suggest 
that PAP was reduced 
because of improved 
endothelial function 
and possibly reverse 
remodeling in some 
patients.
Arias
[60], 2006 
precapillary PH
in OSAS and 
CPAP
randomized 
sham control 
crossover, 
2 × 12 weeks
23 OSA, 
10 controls
sPAP reduction by 5 mm Hg,
sPAP in OSA >controls
OSA induces 
precapillary PH
Colish
[67], 2012 
precapillary PH
in OSA and 
CPAP
observational, 
prospective 
study on one-
year treatment 
effects
47 OSA, 
AHI 63 ± 30/h
s PAP decreased significantly 
from 54 to 39 mm Hg
Ulrich
[62], 2015  
precapillary PH 
and SBD; effect 
of nocturnal 
oxygen vs. 
placebo and vs. 
acetazolamide
randomized, 
double-blind 
double 
crossover
23 patients, with 
precapillary PH; 
16 PAH, 7 CTEPH
oxygen improved 6-min walk 
distance after 1 week of treatment, 
acetazolamide had no 
significant effect compared to 
placebo. Both oxygen and 
acetazolamide improved the 
AHI and nocturnal oxygenation; 
sPAP did not change with any 
of the treatments
nocturnal oxygen 
therapy also improved 
nocturnal 
oxygenation, periodic 
breathing, functional 
class and indices right 
ventricular function
Marvisi
[68], 2015 
precapillary PH
in OSA, effect 
of CPAP and 
UPPP
observational 
case study, 
before and 
after CPAP 
or UPPP
25 of 75 with 
OSA and elevated 
mPAP
17 treated with CPAP, 8 with 
upper airway surgery, sPAP 
reduction from mean 40 to 25 
mm Hg (CPAP) and 22 mm Hg 
(surgery), n.s. between groups
CPAP and UPPP 
cohort differed largely 
in BMI at baseline
PH, pulmonary hypertension; OSA(S), obstructive sleep apnea (syndrome); CPAP, continuous positive airway pressure; AHI, apnea/
hypopnea index;  mPAP, sPAP, mean and systolic pulmonary artery pressure estimated by echocardiography; BMI, body mass index; 
BP, blood pressure; CTEPH, chronic thromboembolic pulmonary hypertension; PAH, pulmonary arterial hypertension; SDB, sleep 
disordered breathing; UPPP,  uvulopalatopharyngoplasty.
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tients with nighttime hypoxemia and SBD. In the only 
randomized, placebo-controlled study in patients with 
precapillary PH and SDB nocturnal oxygen therapy im-
proved the 6-min walk distance already after 1 week 
( Fig. 5 ) and reduced the AHI  [62] . In turn, acetazolamide 
(2 × 250 mg tablets/day) reduced the AHI to a similar de-
gree but did not change the 6-min walk distance  [62] . 
Whether selected patients with PAH and SDB may ben-
efit from specific PH therapy has not been studied.  Ta-
ble  3 gives an overview of interventional studies with 
CPAP or oxygen in patients with SBD associated precap-
illary PH.
 Conclusions 
 Available data suggest that about one half of patients 
with OSA unselected for the absence of comorbidities 
have intermittent or sustained elevations of the PAP and 
that up to one half of patients with precapillary PH suffer 
from SBD. Several pathophysiologic mechanisms predis-
pose patients with SBD to precapillary PH. However, 
precapillary PH in OSA not associated with any other 
conditions leading to hypoxemia seems to be rare. Opti-
mized therapy of any comorbidity such as COPD and 
obesity seems to be crucial. For the remaining patients 
with both SDB and PH but without comorbidity, positive 
pressure ventilation or oxygen might be beneficial in 
terms of lowering the PAP but this has not been evalu-
ated in rigorous randomized trials. In patients with pre-
capillary PH associated with SDB nocturnal oxygen sup-
plementation has improved exercise performance and 
SDB in one trial  [62] but long-term studies that confirm 
these findings are lacking. The role of CPAP or other 
modes of positive pressure ventilation and of PH spe-
cific drugs in the treatment of patients with precapillary 
PH and central or OSA requires further evaluation in 
randomized trials.
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